In our in vitro study, aspirin normalized the expression of biomarkers related to atherosclerosis and NAFLD in disease-mimicking conditions, and the effects of aspirin may be regulated by the PPARδ-AMPK-PGC-1α pathway. Here, PPARD is linked to metabolic dysfunction-associated steatotic liver disease.